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Abstract
Background
New interventions for tuberculosis are urgently needed. Non-human primate (NHP) models
provide the most relevant pre-clinical models of human disease and play a critical role in
vaccine development. Models utilising Asian cynomolgus macaque populations are well
established but the restricted genetic diversity of the Mauritian cynomolgus macaques may
be of added value.
Methods
Mauritian cynomolgus macaques were exposed to a range of doses of M. tuberculosis deliv-
ered by aerosol, and the outcome was assessed using clinical, imaging and pathology-
based measures.
Results
All macaques developed characteristic clinical signs and disease features of tuberculosis
(TB). Disease burden and the ability to control disease were dependent on exposure dose.
Mauritian cynomolgus macaques showed less variation in pulmonary disease burden and
total gross pathology scores within exposure dose groups than either Indian rhesus
macaques or Chinese cynomolgus macaques
Conclusions
The genetic homogeneity of Mauritian cynomolgus macaques makes them a potentially
useful model of human tuberculosis.
1. Introduction
Mycobacterium tuberculosis (M. tuberculosis), the causative agent of tuberculosis (TB), is
responsible for 9 million new infections and 1.5 million deaths each year [1]. Tuberculosis is
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an enormous global health issue due to the rise in drug-resistant strains, the impact of co-
infection with HIV, and the estimate that a third of the world’s population could be latently
infected. Vaccination is widely accepted to be the most effective method for infectious disease
control, and although the only licenced vaccine against M. tuberculosis, Bacille Calmette-Gur-
e´in (BCG), protects children from developing severe TB disease [2], the protection afforded to
adults is limited [3], and it is unsuitable for use in people whose immune system is compro-
mised, so more effective vaccines against M. tuberculosis are desperately needed.
Preclinical animal models are critical to the development of new vaccines, as studies of
infectious challenge can be used to predict the effectiveness of vaccines in humans and they
provide the opportunity to identify and validate correlates of protection. Due to their close
similarity to humans, non-human primates offer the most relevant models of human diseases,
and models of M. tuberculosis have been established in both rhesus macaque (Macaca mulatta)
and cynomolgus macaque (Macaca fascicularis) species [4–6] with cynomolgus macaques
showing an improved ability to control M. tuberculosis-induced disease [7, 8]. To date, the
cynomolgus macaque models reported have employed Asian cynomolgus macaques from
either China or the Philippines [9–12] and studies have shown these populations to exhibit a
full spectrum of outcomes to M. tuberculosis challenge, from latent infection to the develop-
ment of active progressive disease [4], which is likely to be a reflection of their wide genetic
diversity.
Cynomolgus macaques are indigenous to mainland Southeast Asia, and surrounding
islands such as Sumatra and the Philippines, but have also been introduced as an alien species
in several locations, including the island of Mauritius. The Mauritian cynomolgus macaque
population that descended from the small founder group consequently show a reduced genetic
variability [13]. Consequently, differences in genetic composition [14] and phenotypic charac-
teristics, such as body weight [15], sexual maturation rate [16], blood chemistry and haematol-
ogy [17], and microbiome [18] compared with populations from within the species natural
range of habitats in Asia have been reported. Furthermore, developments in the immunoge-
netic characterisation of Mauritian cynomolgus macaques have identified their value in the
study of the role of host MHC genetics in immunogenicity and vaccine studies [19–27]. Thus,
the Mauritian cynomolgus macaque has the potential to provide an important addition to the
portfolio of macaque models of M. tuberculosis. A less genetically diverse population may,
respond more reproducibly to infection, enhancing the ability to discriminate protective
effects afforded by new vaccine candidates and facilitate the identification of much needed
immune correlates of protection. The pilot study reported here aimed to establish an aerosol
challenge model of TB in Mauritian cynomolgus macaques, and evaluate the effect of different
challenge doses of M. tuberculosis on the clinical outcome.
2. Materials and methods
2.1 Experimental animals
Nine captive-bred cynomolgus macaques of Mauritian genotype aged between 2 and 4 years
were obtained from an established UK breeding colony [28]. Absence of previous exposure to
mycobacterial antigens (M. tuberculosis infection or environmental mycobacteria) was con-
firmed by the tuberculin test whilst the animals were still in their original breeding colony, and
just prior to study start, by the IFN-γ based Primagam™ test kit (Biocor Animal Health Inc,
Ohama, Nebraska, USA) and an ex-vivo IFN-γ ELISPOT (Mabtech AB, Nacka Strand, Swe-
den) to measure responses to mycobacterial antigens: PPD (Statens Serum Institute, Copenha-
gen, Denmark), and pooled 15-mer peptides of ESAT6 and CFP10 (Peptide Protein Research
LTD, Fareham, UK). Animals were housed in compatible social groups, in accordance with
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the Home Office (UK) Code of Practice for the Housing and Care of Animals Used in Scien-
tific Procedures (1989), and the National Committee for Refinement, Reduction and Replace-
ment (NC3Rs) Guidelines on Primate Accommodation, Care and Use, August 2006 (NC3Rs,
2006) in cages approximately 2.5M high by 4M long by 2M deep. These cages were constructed
with high level observation balconies and with a floor of deep litter to allow foraging. Further
enrichment was afforded by the provision of toys, swings, feeding puzzles and DVDs for visual
stimulation. In addition to standard old world primate pellets further food was provided by a
selection of vegetables and fruit. Animals were sedated by intramuscular injection of ketamine
hydrochloride (Ketaset, 100mg/ml, Fort Dodge Animal Health Ltd, Southampton, UK; 10mg/
kg) for procedures requiring their removal from their housing. None of the animals had been
used previously for experimental procedures and each socially compatible group was ran-
domly assigned to a particular study treatment. All animal procedures and study design were
approved by the Public Health England, Porton Down Ethical Review Committee, and autho-
rized under an appropriate UK Home Office project license.
2.2 M. tuberculosis strain
The M. tuberculosis Erdman strain K01 used for challenge was provided by the CBER/FDA
repository and prepared from frozen suspensions at a stated titre of 3.5 ± 1.5x108 CFU/ml. For
challenge, sufficient vials were thawed and diluted appropriately, as stated below, in sterile dis-
tilled water.
2.3 Aerosol exposure
Macaques were challenged by exposure to aerosols of M. tuberculosis as previously described
[29–31]. Mono-dispersed bacteria in particles were generated using a 3-jet Collison nebuliser
(BGI) and, in conjunction with a modified Henderson apparatus [32], delivered to the nares of
each sedated primate via a modified veterinary anaesthetic mask. Challenge was performed on
sedated animals placed within a ‘head-out’, plethysmography chamber (Buxco, Wilmington,
North Carolina, USA) to enable the aerosol to be delivered simultaneously with the measure-
ment of respired volume. The aerosol delivery process was designed to result in the deposition
of a defined spread of target doses ranging from 22–250 CFU retained in the lungs (Table 1).
This range of low and very high challenge doses was selected because the susceptibility of this
species of macaque to TB was unknown. The number of bacilli deposited and retained in the
lungs of macaques cannot be measured directly, and so quantification of the dose is calculated
from the concentration of viable organisms in the aerosol (Caero) and the volume of aerosol
inhaled by the animal. This ‘presented dose’ (PD) is the number of organisms that the animals
inhale. Caero is either measured directly using air sampling within the system or may be calcu-
lated using the concentration of organisms in the nebulizer (Cneb) and a ‘spray factor’ that is a
constant derived from data generated for the specific organism with identical aerosol exposure
parameters. The calculations to derive the PD and the retained dose (the number of organisms
assumed to be retained in the lung) have been described previously for high/medium aerosol
doses [30, 31]. The assumed retained dose was calculated from the PD by applying a retention
factor. Retention factors for rhesus macaques are described by Harper and Moreton [33].
2.4 Clinical assessment
Animals were monitored daily for behavioural abnormalities including depression, withdrawal
from the group, aggression, and changes in feeding patterns, respiration rate and the occurrence
of cough. Animals were weighed, rectal temperature measured and examined for gross abnor-
malities on each occasion that required blood sample collection, aerosol challenge or euthanasia.
Tuberculosis model in Mauritian cynomolgus macaques
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Red blood cell (RBC) haemoglobin levels were measured using a HaemaCue haemoglobin-
ometer (Haemacue Ltd, Dronfield, UK) to identify the presence of anaemia, and erythrocyte sed-
imentation rates (ESR) were measured using the Sediplast system (Guest Medical, Edenbridge,
UK) to detect and monitor inflammation induced by infection with M. tuberculosis.
The time of necropsy, if prior to the end of the planned study period, was determined by
experienced primatology staff and based on a combination of the following adverse indicators:
depression or withdrawn behaviour, abnormal respiration (dyspnoea), loss of 20% of peak
post-challenge weight, ESR levels elevated above normal (>20 mm), haemoglobin level below
normal limits (< 100g/dL), increased temperature (>41˚C) and abnormal thoracic radiograph.
The range of adverse indicators used allowed application of humane intervention when indi-
viduals had progressed to moderate disease.
2.5 Immune response analysis
2.5.1 Interferon-gamma (IFN-γ) ELISpot. The M. tuberculosis-specific immune response
was evaluated at two weekly intervals throughout the study. Peripheral blood mononuclear
cells were isolated from heparin anti-coagulated blood using standard methods. An IFN-γ ELI-
Spot assay was used to estimate the numbers and IFN-γ production capacity of mycobacteria-
specific T cells in PBMCs using a human/simian IFN-γ kit (Mabtech AB, Nacka Strand, Swe-
den), as described previously [30]. Cells were stimulated with PPD (10 μg/ml, SSI, Copenha-
gen, Denmark) or pools of overlapping 15mer peptides spanning CFP10, or ESAT6 (Peptide
Protein Research Ltd, Wickham, UK).
2.5.2 Quantification of secreted IFN-γ. IFN-γ production was measured using a whole
blood ELISA as previously described [30]. In brief, heparinised blood was diluted 1 in 10 with
serum-free medium (RPMI supplemented with L-glutamine, penicillin and streptomycin) and
cultured with purified protein derivative from M. tuberculosis (PPD; 5 μg/ml, SSI, Copenha-
gen, Denmark), or mitogen Phytohaemaglutinin (PHA; Sigma-Aldrich, Dorset, UK) (5μg/l),
or in medium alone for 6 days. Supernatants were harvested at day 6 and stored at -80˚C. The
quantity of IFN-γ in the supernatants was estimated using a commercially available human/
monkey IFN-γ ELISA kit (Mabtech AB, Nacka Strand, Sweden). A purified human IFN-γ was
used for the standard curve on each plate. The ELISA was developed using streptavidin and
3,3’,5,5’-tetramethylbenzidine (TMB) liquid substrate system (Sigma-Aldrich, Dorset, UK)
and the reaction stopped with 2M sulphuric acid (May & Baker Ltd, Dagenham, UK). ELISA
plates were read at 450nm. A standard curve was plotted for each plate and used to calculate
the concentrations of IFN-γ in each sample.
Table 1. Aerosol challenge doses of M. tuberculosis delivered to Mauritian cynomolgus macaques.
Animal Identification number Presented Dose range (CFU) Presented Dose (CFU) Estimated Retained Dose [30,31]. (CFU)
M982B Very high [>1400] 1650 236
I131B 1624 232
M651 1544 221
M284D High 522 75
[500–1400]
I319DB Medium [250–500] 448 64
I347G 335 48
M054E 302 43
M064D Low 242 35
M988E [<250] 153 22
doi:10.1371/journal.pone.0171906.t001
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2.6 Necropsy
Prior to euthanasia by intra-cardiac injection of a lethal dose of anaesthetic (Dolelethal, Ve´toqui-
nol UK Ltd, 140mg/kg), animals were anaesthetised and clinical data collected. Blood samples
were taken. A post-mortem examination was performed immediately and gross pathological
changes were scored using an established system based on the number and extent of lesions pres-
ent in the lungs, spleen, liver, kidney and lymph nodes, as described previously [30, 31]. Samples
of spleen, liver, kidneys and tracheobronchial, inguinal and axillary lymph nodes were removed
and sampled for quantitative bacteriology. The lungs, including the heart and lung-associated
lymph nodes, were removed intact and the lymph nodes examined for lesions. The complete
lung set was fixed by intra-tracheal infusion with 10% neutral buffered formalin (NBF) using a
syringe and 13CH Nelaton catheter (J.A.K. Marketing, York, UK). The catheter tip was inserted
into each bronchus in turn via the trachea; the lungs were infused until they were expanded to a
size considered to be normal inspiratory dimensions, and the trachea ligated to retain the fluid.
The infused lung was immersed in 10% NBF. In addition, samples of kidneys, liver, spleen, and
sub-clavicular, hepatic inguinal and axillary lymph nodes were fixed in 10% NBF.
2.7 Lung imaging
Thoracic radiographs (SP VET 3.2, Xograph Ltd) were acquired using mammography film
(Xograph Imaging Systems Ltd, Tetbury, UK) before and every 2 weeks after exposure to M.
tuberculosis. Evaluation of disease was performed by an experienced consultant thoracic radi-
ologist blinded to the exposure dose and clinical status using a pre-determined scoring system
based on the amount and distribution of infiltrate as previously described [31].
2.8 Magnetic resonance (MR) imaging
The ex-vivo expanded, fixed lungs were set in 2% agarose (Sigma-Aldrich, UK) and images
were collected using a 3.0 T 750 MR Scanner (General Electric Healthcare, Milwaukee, WI,
USA) as described previously [31]. This enabled evaluation of the pulmonary disease burden
at the end of the study period. Lung lesions were identified in MR images from their signal
intensity and nodular morphology relative to normal lung parenchyma.
2.9 Lesion analysis / quantification (stereology)
Lung lesions were identified on MR images based on their signal intensity and nodular mor-
phology relative to more normal lung parenchyma. The total lung and lesion volume relative
to the fixed tissue was determined using the Cavalieri method applied to MRI image stacks,
and then expressed as a ratio to provide a measure of disease burden in each animal, as previ-
ously described [30, 31]. Analyses of lesion volume on MR images were performed with the
investigators reading the images blind to treatment groups.
2.10 Pathology studies
2.10.1 Gross examination following fixation. The fixed lungs were sliced serially and
lesions counted as described previously31. Each lung lobe was evaluated separately and discrete
lesions in the parenchyma were counted. Where lesions had coalesced, these were measured
and recorded. Lung-associated lymph nodes, particularly around the tracheal bifurcation,
were dissected and examined. The remaining tissues were examined during trimming.
2.10.2 Histopathological examination. Representative samples from each lung lobe and
other organs were processed to paraffin wax, sectioned at 3–5 μm, and stained with haematox-
ylin and eosin (HE). For each lung lobe, tissue slices containing obvious lesions were chosen
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for histological examination. Where gross lesions were not visible, a sample was taken from a
pre-defined anatomical location from each lobe to establish consistency between animals. The
nature and severity of the microscopic lesions was evaluated subjectively by a pathologist who
was blinded to the treatment groups to prevent bias. Lesions were classified according to the
scheme used by Lin [34]. In non-pulmonary tissue, the occurrence of tuberculosis induced
lesions was scored as present or absent.
2.11 Bacteriology
The spleen, kidneys, liver and tracheobronchial lymph nodes were sampled for the presence of
viable M. tuberculosis post-mortem31. Where available, tissue sections with and without visible
tuberculous lesions were collected for analysis. Weighed tissue samples were homogenized in
2 ml of sterile water, and either serially diluted in sterile water prior to being plated or plated
undiluted directly onto Middlebrook 7H11 OADC selective agar. Plates were incubated for
three weeks at 37˚C and resultant colonies were confirmed as M. tuberculosis and counted.
Mean Colony forming unit (CFU) per gram from each tissue sample were determined.
2.12 Statistical analyses
Differences in the pathology scores, pulmonary disease measures and clinical measures of dis-
ease burden at the end of study were compared between test groups using the non-parametric
Mann-Whitney U test, in Graphpad Prism, version 5.01 (GraphPad Software Inc, La Jolla, Cal-
ifornia, USA). The Spearman correlation test was used to determine the level of correlation
between study parameters using GraphPad Prism, version 5.01 (GraphPad Software Inc, La
Jolla, California, USA).
3. Results
3.1 M. tuberculosis exposure and disease progression post-challenge
Nine Mauritian cynomolgus macaques were exposed to aerosols containing a planned wide
spread of estimated retained doses of M. tuberculosis ranging from 22–236 CFU (Table 1) and
monitored for changes in behaviour and clinical parameters for up to 13 weeks after challenge.
Disease progressed in five of nine animals to a level that met the humane endpoint criteria for
moderate disease. In the three macaques (M982B, I131B, M651) that received the very high
estimated retained aerosol doses of M. tuberculosis (236, 232, and 221 CFU), disease progressed
rapidly and they were euthanized six or seven weeks after challenge. In the days prior to eutha-
nasia, all three animals showed changes in their behaviour, including reduction in feeding and
drinking, increased respiratory rates, ruffled coat condition. Two of the three (M982B and
I131B) also became withdrawn or depressed and coughing was observed (Table 2). All three
macaques also showed abnormal thoracic radiographs and clinical parameters that deviated
from normal ranges that included weight loss, anaemia, and increased ESR (Fig 1).
The macaques which received the six lower doses of M. tuberculosis developed increased
respiratory rates between week 6 and 12 after aerosol exposure and cough during weeks seven,
eight and nine. Ten weeks after challenge, macaque M284D, who received a high estimated
retained dose (75 CFU) of M. tuberculosis, was euthanized as the level of disease had pro-
gressed to meet humane end point criteria. The five macaques that were exposed to medium
or low doses of M. tuberculosis exhibited normal behaviour and changes in weight, haemoglo-
bin level, temperature ESR that did not exceed the normal limits, although abnormalities were
detected on thoracic radiographs (Fig 1). These five animals were euthanized as planned, dur-
ing the 12th (M988E, I319D, I347G) or 13th (M054E, M064D) week after challenge. Macaque
Tuberculosis model in Mauritian cynomolgus macaques
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M988E, that was exposed to the lowest dose of M. tuberculosis (22 CFU), became withdrawn
and on the day of euthanasia, exhibited chronic anaemia and a body weight loss in line with
endpoint criteria.
3.2 IFN-γ response following aerosol challenge with M. tuberculosis
The Mycobacterium-specific IFN-γ response was measured by ELISpot (Fig 2A, 2B and 2C)
and ELISA (Fig 2D) applied at two weekly intervals throughout the study. High frequencies of
IFN-γ producing cells measured by ELISpot were detected four to six weeks after challenge in
the three macaques (M982B, I131B, M651) exposed to the highest doses of M. tuberculosis. The
peak response to PPD was detected six weeks after challenge, while the highest responses to
ESAT6 and CFP10 were measured four weeks after challenge; however, responses to these two
antigens were not measured at week six in these three animals as cells were not available. Of
the six macaques exposed to the lower doses, responses remained low until ten or twelve weeks
after challenge, when M988E and M064D made responses above pre-infection levels to all
three antigens, in contrast I319DB responded to ESAT6 and CFP10 but not PPD, while
M284D responded to CFP10 and PPD. Responses to PPD, ESAT6 or CFP10 above pre-infec-
tion levels were not detected in I347G and M054E following exposure to M. tuberculosis.
Table 2. Contra-indicators observed in cynomolgus macaques of Mauritian origin following aerosol infection with M. tuberculosis.
Animal I.
D.
Estimated Retained Dose M.
tuberculosis
Indicators observed
post challenge. (week
post challenge
indicator recorded)
Indicators observed prior to euthanasia
Respiration
rate
Cough Behaviour Eating /
drinking
Respiration rate Under
sedation
Other indicators
M982B 236 Rapid Yes Depressed
withdrawn
No / No Rapid / Shallow Very ruffled coat.
Thin(5–6) (8)
I131B 232 Rapid Yes Depressed No / No Rapid / Shallow Very ruffled coat
(5–6) (5)
M651 221 Rapid No Normal No / No Rapid / Laboured Ruffled coat,
Thin(5–6)
M284D 75 Rapid Yes Normal Normal Rapid / Shallow NAD
(6–10) (6, 7,
8)
I319DB 64 Rapid Yes Normal Normal Rapid laboured NAD
(7–12) (6, 7,
8)
I347G 48 Rapid Yes Normal Normal Rapid / Shallow NAD
(6–12) (6, 7,
8)
M054E 43 Rapid Yes Normal Normal Normal NAD
(7–12) (6, 7,
8)
M064D 35 Rapid Yes Normal Normal Normal NAD
(7–12) (6, 7,
8)
M988E 22 Rapid Yes Depressed
Withdrawn
Normal Rapid NAD
(7–12) (6, 7,
8)
NAD: No abnormalities detected.
doi:10.1371/journal.pone.0171906.t002
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Evaluation by ELISA of blood collected from M064D at four, six and ten weeks and from
M284D at four weeks after challenge, produced high levels of IFN-γ following stimulation with
PPD, which was in contrast to the very low levels secreted by blood collected from the other
seven animals during the study.
3.3 Measures of tuberculosis-induced disease burden
At the end of the study, the level of M. tuberculosis-induced disease burden was determined
using a range of approaches that have been used previously for the evaluation of TB disease in
both rhesus [30, 31] and cynomolgus macaques [31] (Fig 1). M. tuberculosis -induced disease
burden measured by total pathology score (Fig 1A) and the clinical markers of weight loss (Fig
1B), increased in ESR (Fig 1C) and reduction in red blood cell haemoglobin concentration
(Fig 1D) showed non-significant trends to be higher in the four animals exposed to very high,
or high aerosol doses of M. tuberculosis relative to those receiving lower dose challenge. Fur-
thermore, these high and very high dose animals developed symptoms indicative of progres-
sive disease and met humane endpoint criteria, whilst the five animals exposed to lower doses
controlled disease progression to the end of the study.
The level of pulmonary disease measured by MR stereology, gross pathology score and
chest radiograph score was significantly higher in the four macaques that were exposed to very
high or high challenge doses than in the macaques exposed to medium or low doses of M.
tuberculosis (MR stereology: p = 0.0159, gross pathology score: p = 0.0238, chest radiograph
Fig 1. Measures of pulmonary disease and clinical disease severity in Mauritian cynomolgus macaques following aerosol exposure to a
range of doses of M. tuberculosis. Black fill colour represents animals in which disease progressed rapidly and met endpoint criteria prior to the
end of the study. Panel A: the total pathology score determined using a quantitative scoring system; Panel B: % weight loss from peak post-challenge
weight on the day of euthanasia; Panel C: Erythrocyte sedimentation rate (ESR) on the day of euthanasia, or seven days prior to euthanasia (M982B,
I131B, M988E); Panel D: Red blood cell haemoglobin concentration (RBC[Hb]) on the day of euthanasia; Panel E: the lung to lesion volume ratio
determined using MR stereology; Panel F: number of lesions in the lung enumerated by serial sectioning and manual counting; Panel G: the scores
attributed to the pulmonary component as part of the total pathology score; Panel H: score attributed to the chest radiogram on the day of euthanasia;
TNTC indicates too numerous to count.
doi:10.1371/journal.pone.0171906.g001
Tuberculosis model in Mauritian cynomolgus macaques
PLOS ONE | DOI:10.1371/journal.pone.0171906 March 8, 2017 8 / 19
score: p = 0.0479) and increased in line with the exposure dose (Fig 1E–1H). The Spearman’s
Rank correlation test revealed significant relationships between exposure dose and lung dis-
ease burden quantified by MR stereology (p =<0.0001, r = 0.9833), lung gross pathology (p =
<0.0001, r = 0.9748), chest radiograph score (p = 0.0079, r = 0.8572), ESR (p = 0.0028, r = 1.00)
(Fig 3A, 3B, 3C and 3D) and survival time after challenge (Fig 2E). Three-dimensional images
constructed from the MR scans demonstrated the relationship between disease burden and
exposure dose and showed the lesions to be evenly distributed throughout all of the lobes of
the lung (Fig 4). Macroscopic examination confirmed the pulmonary lesions in animals
exposed to higher doses of M. tuberculosis, to be more severe than in animals receiving lower
dose challenge (Table 3). An atypical combination of mature mild lesions with very numerous,
small miliary lesions was noted in animal M988E.
Sections of lung, hilar lymph node, liver, hepatic lymph node, kidney and spleen from all
nine animals were microscopically examined for the presence of tuberculous lesions, and gran-
ulomas were classified according to the scheme used by Lin et al [34] (Table 4). Tuberculous
granulomas varying in nature from unorganised to caseated were detected in all animals; case-
ated lesions were more extensive in animals that received the higher doses. Calcification of
caseated tissue was observed in I319DB (lung), M064D (lung) and M988E (spleen). M988E
was exceptional, in that superimposed on the caseated granulomas was what appeared to be a
more recent development of numerous, small, multifocal granuloma, principally present in
lung, liver and kidney.
3.4 Extra-pulmonary organ-specific bacterial burden
The level of bacterial burden was evaluated in the liver, spleen, kidneys and hilar lymph nodes
in all animals. A similar frequency of isolation from tissues and level of bacterial burden was
Fig 2. Immune responses after aerosol challenge with M. tuberculosis. The frequency of Mycobacterium-specific IFN-γ secreting cells
measured after challenge by ELISpot is shown in panels A (PPD), B (CFP10) and C (ESAT6). Panel D shows the profile of IFN-γ secretion by PPD-
stimulated whole blood measured by ELISA. Exposure to M. tuberculosis at week 0 is indicated by the dotted line.
doi:10.1371/journal.pone.0171906.g002
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seen across all animals although there was a trend for tissues collected from M998E to have
higher bacterial loads than comparable tissues from the other eight macaques (Fig 5).
4. Discussion
This is the first report of the effect of exposure dose on the outcome of infection with M. tuber-
culosis in a more genetically homogeneous species of non-human primate. Mauritian cyno-
molgus macaques were susceptible to aerosol exposure to M. tuberculosis, and displayed
clinical signs and disease features similar to those reported in rhesus and Chinese cynomolgus
macaques following exposure to the same M. tuberculosis strain [30, 31]. All of the challenged
Mauritian cynomolgus macaques exhibited clinical signs typical of active human tuberculosis
and developed lung lesions with both a gross and microscopic pathology similar to that
described previously in TB-infected rhesus and Asian macaques [4, 5, 31, 34]. The key features
of the pathological changes were consistent with those described in human infections includ-
ing a heterogeneity in lesion type and distribution, within and between individuals [35].The
pattern of pulmonary disease was typical of experimental aerosol exposure with lesions distrib-
uted throughout the lung [31, 36] while the burden of disease was directly related to the aerosol
exposure dose.
In order to make a direct comparison of the disease induced in Mauritian cynomolgus
macaques with that in Chinese cynomolgus and rhesus macaques, an analysis of previously
published studies was made where the only variable was the macaque type. Whilst the numbers
in this study are small, the findings suggest that Mauritian cynomolgus macaques have only a
limited ability to control disease, which appears to be lower than that of Chinese cynomolgus
macaques and equivalent to, or potentially even less than that of rhesus macaques (Table 5).
Fig 3. Correlation plots comparing the challenge dose (estimated retained) of M. tuberculosis with disease outcome measured by either lesion
volume to lung volume ratio (A), lung gross pathology score (B), Chest radiograph score (C), erythrocyte sedimentation rate (D), or survival time post
challenge (E). Data points represent individual animals, and vaccination groups are indicated by colour. Spearman’s correlation coefficient (r) and
significance values (p) are indicated.
doi:10.1371/journal.pone.0171906.g003
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The very high presented aerosol exposure doses (1544–1650 CFU) applied to macaques
M982B, I131B, and M651 were selected to match the doses presented (1470–1575 CFU) to rhe-
sus macaques and Chinese cynomolgus macaques in a previously reported study [31] to allow
direct comparison of susceptibility among macaque types. Dose comparison between these
studies was performed on the basis of the ‘presented dose’ of M. tuberculosis rather than the
Fig 4. Magnetic resonance (MR) images of lungs from Mauritian cynomolgus macaques following aerosol infection with a range of doses
of M. tuberculosis.
doi:10.1371/journal.pone.0171906.g004
Tuberculosis model in Mauritian cynomolgus macaques
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‘estimated retained dose’, due to refinements only more recently applied to the method to esti-
mate the retained dose [8]. Unlike the three Chinese cynomolgus macaques who controlled
disease during the thirteen weeks after very high dose challenge, but similar to the Indian rhe-
sus macaques, progressive disease developed rapidly and endpoint criteria were met seven
weeks after challenge in all three of the Mauritian cynomolgus macaques. Both rhesus and Chi-
nese cynomolgus macaques controlled the disease induced following exposure to a high dose
challenge of 630 CFU, the lowest dose presented in the study reported by Sharpe et al [31], for
the full 13 week post-exposure period. In contrast, Mauritian cynomolgus macaque M284D,
the only animal in this study to receive an equivalent high challenge dose, developed disease
that met end point criteria ten weeks after challenge and showed a higher level of pulmonary
disease measured by lesion: lung volume ratio than that measured in either rhesus or Chinese
cynomolgus macaques exposed to similar doses. It is noteworthy that the clinical signs of
cough and altered respiratory rates occurred in all Mauritian cynomolgus macaques exposed
to high, medium and low doses of TB, but only occurred in a proportion of Indian rhesus
macaques and were not seen in Chinese cynomolgus macaques after high dose challenge. Fur-
thermore, one of the Mauritian cynomolgus macaques, (M988E) that received a low challenge
dose developed miliary TB which perhaps suggests a lack of ability to adequately control pri-
mary infection. Thus, the Mauritian cynomolgus macaques displayed a response to infection
Table 3. Summary of lung lesions at dissection of fixed lungs.
Animal
#
Dose
(cfu)
Discrete
lesions
Coalesced
lesions
Range of size of coalesced lesions (mm) Comments
right left right left
M982B 236 TNTC 250 TNTC 18 80% consolidation of right upper 1; 25 x 20 x
15 lesion in right middle. A whole section of
left lobe occupied by coalesced lesions.
Multifocal granulomatous pneumonia with extensive
coalesced lesions. Fibrous adhesions between lobes.
Hilar lymph nodes enlarged and caseous.
I131B 232 TNTC TNTC TNTC TNTC 80–90% consolidation of left lung Multifocal granulomatous pneumonia with extensive
coalesced lesions. Fibrous adhesions between lobes.
Left lobes fused
M651A 221 TNTC TNTC TNTC TNTC 80–90% consolidation of left lung Multifocal granulomatous pneumonia with extensive
coalesced lesions. Fibrous adhesions between lobes
and with parietal pleura. Left lobes fused
M284D 75 TNTC TNTC TNTC TNTC 8 X 6 to 22 x 12 Lesions too numerous to count and too extensive to
measure in right and left lobes. Consolidation
estimated as 70–80%. Severe pathology.
I319DB 64 224 TNTC 37 TNTC 4 x 6 to 15 x 18 Lesions too numerous to count and too extensive to
measure in left lobes. Consolidation estimated as 80–
90%. Widespread fibrous adhesions between upper
and lower lobes of right and left lungs. Moderate/
severe pathology
I 347G 48 TNTC 116 TNTC 9 5 x 4 to 30 x 30 Lesions too numerous to count and too extensive to
measure in left lobes. Consolidation estimated as 86–
80%. Fibrous adhesions between right lung lobes.
Moderate/severe pathology.
M054E 43 150 110 17 15 5 x 5 to 12 x 15 Multifocal granulomatous pneumonia with coalesced
lesions. Mild/moderate pathology.
M064D 35 174 110 11 13 5 x 5 to 12 x 10 Multifocal granulomatous pneumonia with coalesced
lesions. Mild pathology
M988E 22 74 36 3 10 5 x 8 to 20 x 15 All lobes contained multiple miliary lesions that were
too small and numerous to count. Fibrous adhesions
were present between left upper and lower lobes.
Atypical pathology
TNTC: Too numerous to count.
doi:10.1371/journal.pone.0171906.t003
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Table 4. Summary of granuloma distribution.
Animal Dose (cfu) Tissue Type of granuloma
Unorg Solid Neutro Caseated Coalesced
M982B 236 Hilar LN + +
Lung + + + +
Liver
Kidney +
spleen + +
I131B 232 Hilar LN +
Lung + +
Liver + +
Kidney + +
spleen + + +
M651A 221 Hilar LN +
Lung + + + + +
Liver + + + +
Kidney + + + +
spleen + + + +
M284D 75 Hilar LN +
Lung + + + + +
Liver +
Hepatic LN +
Kidneys
Spleen
I319DB 64 Hilar LN +
Lung + + + + +
Liver + + +
Kidneys +
Spleen
1347G 48 Hilar LN +
Lung + + + +
Liver +
Kidneys +
Spleen +
M054E 43 Hilar LN +
Lung + + + + +
Liver + +
Hepatic LN +
Kidneys
Spleen + + + +
M064D 35 Hilar LN +
Lung + + + +
Liver +
Hepatic LN + +
Kidneys
Spleen + +
(Continued )
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which was more like that of rhesus macaques which has been described as a response resem-
bling active TB in susceptible humans [4]. While further work is needed to fully elucidate the
difference between these macaque populations, it is clear that geographic origin, as well as spe-
cies, are important considerations in study design.
The Mauritian cynomolgus macaque has been of particular value in HIV vaccine research
[37] where MHC homogeneity has reduced the variability between animals after vaccination
and has enhanced comparisons of vaccine regimens. In addition, the improved consistency in
outcome has facilitated the use of fewer animals to obtain statistically significant results than if
cynomolgus macaques of Chinese or Vietnamese origin were used [37]. In this study, the Mau-
ritian cynomolgus macaques showed less variation in pulmonary disease burden measured as
the ratio of lesion volume to lung volume ratio and total gross pathology scores within expo-
sure dose groups, than in either Indian rhesus macaques or Chinese cynomolgus macaques
(Table 5). These preliminary observations support the hypothesis that Mauritian cynomolgus
macaques could provide a model with a more homogeneous outcome of TB infection. More
work is needed to define the variation in outcome of exposure to low or ultra-low aerosol
doses and establish an optimal dose for challenge in vaccine efficacy studies.
The Mauritian cynomolgus macaque offers the potential to be an important additional
model that could greatly assist the search for correlates of protection and biomarkers of disease
that would have an enormous impact on the evaluation of new TB vaccines. Similar to rhesus
macaques and Asian cynomolgus macaques, Mauritian cynomolgus macaques made mycobac-
teria-specific IFNγ responses following exposure to M. tuberculosis with the frequency of
IFNγ-producing cells reflecting disease burden and therefore antigen load [8]. However it is
the differences in the immune responses made by different macaque populations that provide
an important opportunity that could assist with the elucidation of new biomarkers of disease
and/or correlates of protection. Further work with state-of the-art immunological tools will be
required to fully characterise the response of the Mauritian cynomolgus macaque to M. tuber-
culosis infection and allow cross genotype and species comparisons to expose the mechanisms
responsible for the differences in TB control between macaque species and populations
The genetic homogeneity of the Mauritian cynomolgus macaque population is an asset that
offers the opportunity to further understand the immune response to vaccination and infec-
tion. The relative ease of MHC haplotype characterisation and the high frequency of selected
MHC haplotypes have allowed population studies to be conducted in the HIV field. Possession
of specific MHC class I and II haplotypes have been shown to influence the outcome of experi-
mental infection of Mauritian cynomolgus macaques with SHIVSF162P4cy [38], together with
the immune response induced [39], and these can be associated with superior viraemic control
of SIV or SHIV viruses in naïve-challenged and vaccinated individuals [25–27]. Although the
small size of this study prevented meaningful evaluation of the possession of specific MHC
Table 4. (Continued)
Animal Dose (cfu) Tissue Type of granuloma
Unorg Solid Neutro Caseated Coalesced
M988E 22 Hilar LN +
Lung + + + + +
Liver + +
Kidneys + + +
Spleen +
Unorg: Unorganised; Neutro: neutrophic.
doi:10.1371/journal.pone.0171906.t004
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haplotypes on outcome of M. tuberculosis infection, statistical power will increase as more
studies using this genetic sub-type of the species, presenting the opportunity to identify poten-
tial associations.
In conclusion, this study has shown that Mauritian cynomolgus macaque are susceptible to
aerosol challenge with M. tuberculosis, and develop patterns of disease similar to that reported
in cynomolgus macaques of Asian origin but display an increased susceptibility and reduced
ability to control disease progression. The predisposition to develop high burden disease,
together with, the homogeneity of the occurrence of cough, make this type of macaque an
attractive host for studies of TB transmission. The restricted genetic variability of the
Fig 5. Bacterial burden in extra-pulmonary tissues collected from Mauritian cynomolgus macaques following aerosol infection with a
range of doses of M. tuberculosis. Bars show CFU recovered from samples of spleen (A), liver (B), kidney (C) and Hilar lymph node (D). CFU
recovered from replicate tissue samples are shown as a mean with standard deviation indicated as error bars. Samples for which bacteriology
analysis was not done (ND) are indicated.
doi:10.1371/journal.pone.0171906.g005
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Mauritian cynomolgus macaque population provides an advantage in the battle to elucidate
correlates of protective immunity. Further work is required to develop the Mauritian cynomol-
gus macaque as a model for the evaluation of TB vaccines, particularly the definition of low
and ultra-low aerosol doses suitable for the assessment of vaccine efficacy. However, once
established, the benefits of the Mauritian cynomolgus macaque population recognised by the
HIV field could be unlocked for TB research.
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